April 30, 2015
Boehringer Ingelheim Japan reported on April 28 that its pharmaceutical sales rose 4.5% over the previous year to 250.9 billion yen on an NHI price basis in 2014 driven by the growth of its hypertension treatment Micardis (telmisartan) and dipeptidyl...read more